ENTRY       D11678                      Drug
NAME        Lecanemab (USAN);
            Lecanemab (genetical recombination) (JAN);
            Leqembi (TN)
PRODUCT     LEQEMBI (Eisai)
FORMULA     C6544H10088N1744O2032S46
EXACT_MASS  147088.6818
MOL_WEIGHT  147179.5751
SEQUENCE    (Heqvy chain)
            EVQLVESGGG LVQPGGSLRL SCSASGFTFS SFGMHWVRQA PGKGLEWVAY ISSGSSTIYY
            GDTVKGRFTI SRDNAKNSLF LQMSSLRAED TAVYYCAREG GYYYGRSYYT MDYWGQGTTV
            TVSSASTKGP SVFPLAPSSK STSGGTAALG CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV
            LQSSGLYSLS SVVTVPSSSL GTQTYICNVN HKPSNTKVDK RVEPKSCDKT HTCPPCPAPE
            LLGGPSVFLF PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE
            EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKAKGQP REPQVYTLPP
            SREEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPVLDSDGS FFLYSKLTVD
            KSRWQQGNVF SCSVMHEALH NHYTQKSLSL SPGK
            (Light chain)
            DVVMTQSPLS LPVTPGAPAS ISCRSSQSIV HSNGNTYLEW YLQKPGQSPK LLIYKVSNRF
            SGVPDRFSGS GSGTDFTLRI SRVEAEDVGI YYCFQGSHVP PTFGPGTKLE IKRTVAAPSV
            FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL
            SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
            (Disulfide bridge: H22-H96, H151-H207, H227-L219, H233-H'233, H236-H'236, H268-H328, H374-H432, H'22-H'96, H'151-H'207, H'227-H'219, H'268-H'328, H'374-H'432, L23-L93, L139-L199, L'23-L'93, L'139-L'199)
  TYPE      Peptide
CLASS       Neuropsychiatric agent
             DG01968  Antidementia agent
REMARK      Therapeutic category: 1190
            Product: D11678<JP/US>
EFFICACY    Dementia therapeutic agent
  DISEASE   Alzheimer's disease [DS:H00056]
  TYPE      Monoclonal antibody
COMMENT     Treatment of Alzheimer's disease
TARGET      Amyloid beta [CPD:C16514 C16515]
INTERACTION  
BRITE       USP drug classification [BR:br08302]
             Antidementia Agents
              Antidementia Agents, Other
               Lecanemab
                D11678  Lecanemab (USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             1  Agents affecting nervous system and sensory organs
              11  Agents affecting central nervous system
               119  Miscellaneous
                1190  Miscellaneous
                 D11678  Lecanemab (USAN); Lecanemab (genetical recombination) (JAN)
            Drug groups [BR:br08330]
             Neuropsychiatric agent
              DG01968  Antidementia agent
               D11678  Lecanemab
            Drug classes [BR:br08332]
             Neuropsychiatric agent
              DG01968  Antidementia agent
               D11678  Lecanemab
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11678
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D11678
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11678
            Pharmacogenomic biomarkers [br08341.html]
             Polymorphisms and mutations affecting drug response
              D11678
DBLINKS     CAS: 1260393-98-3
            PubChem: 405226545
///
